QIAGEN welcomes U.S. Preventive Services Task Force reaffirmation for latent TB screening in populations at increased risk

May 8, 2023
News from QIAGEN.

QIAGEN announced that it welcomed the U.S. Preventive Services Task Force (USPSTF) reaffirming a previously issued recommendation for latent tuberculosis infection (LTBI) screening by primary care physicians in populations at increased risk. 

The USPSTF issued a final report on May 2 to continue the “B” recommendation for screening of these populations, building on the previous recommendation issued in 2016 by the independent volunteer panel of experts in prevention and evidence-based medicine. 

This reaffirmation helps ensure that insured patients in the U.S. from risk groups for TB infection continue to have access to screening with no out-of-pocket costs to them, as the Affordable Care Act requires that insurers provide preventive services with an “A” or “B” recommendation at no cost. 

The USPSTF recommendations referred to QuantiFERON-TB Gold Plus (QFT-Plus) from QIAGEN as reliable in screening. It also suggested that interferon gamma release assays (IGRAs) like QFT-Plus may have advantages in certain patient populations over the tuberculin skin test (TST) in a wider group of people at risk for latent TB infection. This is in line with guidelines from the U.S. Centers for Disease Control.  

QIAGEN release